Raz Yirmiya

Dinur et al., A Novel Anti-Inflammatory Formulation Comprising Celecoxib and Cannabidiol Exerts Antidepressant and Anxiolytic Effects. Cannabis and Cannabinoid Research, 2022. [Link]

Goshen et al., Mentoring: A three-generation perspective. Neuron, 110: 363-365, 2022. [Link]

Rimmerman N, et al. Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effs of electroconvulsive stimulation. Molecular Psychiatry, 27: 1120–1135, 2022. [Link]

Reshef R et al. The role of microglia and their CX3CR1 signaling in adult neurogenesis in the olfactory bulb. eLife, 6:e30809, 2017. [Link]

Rimmerman R, et al. The hippocampal transcriptomic signature of stress resilience in mice with microglial fractalkine receptor (CX3CR1) deficiency. Brain Behavior and Immunity, 61: 184-196, 2017. [Link]

Yirmiya R, et al. Depression as a Microglial Disease. Trends in Neurosciences, 38: 637-58, 2015. [Link]

Yirmiya R and Kreisel T. Treatment of mood disorders and stress related disorders. US Granted patent number US9950036B2. April 24, 2018. [Link]

Yirmiya R. Treatment of mood disorders and stress related disorders (CIP). US Granted patent numbe US10626178B2. April 21, 2020. [Link]

Yirmiya R. Microglia modulators for use in treatment of depression. US Application number US2021/10077477A1. March 18, 2021. [Link]

Yirmiya R. Composition comprising cannabinoids, terpenes, and flavonoids for treating depression. WO2022013874A1, July, 14, 2021. [Link]

More Publication

Raz Yirmiya

Laboratory for PsychoNeuroImmunology Research

Contact

Recent Publications